SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Pyth Network is a decentralised oracle network designed to provide real-time financial market data to decentralised applications (dApps) across multiple blockchains. It allows developer to secure smart contracts with reliable, low-latency market data from institutional sources, and build apps with high-fidelity oracle feeds designed for mission-critical systems.

Pyth Network

Pyth Network is trending as the community discusses potential revenue generation and real-world asset (RWA) adoption. Some users are speculating on partnerships and integrations with other projects. Bullish sentiment is fueled by discussions of on-chain matrix rewards and treasury mechanics.

"What's Updog?" is a Community Led token.

UpDog

$UPDOG.X is trending as the community rallies around the long-standing joke and the coin's presence on the Solana network. Community members are actively engaging in the 'What's UpDog?' meme, celebrating its resilience and unique place as the only UPDOG on the Jupiter Strict List.

BYTE is a novel meme token that creatively intertwines the worlds of cryptocurrency and popular culture. Inspired by Grok's answer to "What would you name your dog?", Grok answered, 'Byte.' When Grok was asked who created Byte, it says he was created by the xAI team lead by Elon Musk as a gift to Grok AI to keep him company in the metaverse. BYTE serves as a playful reference to the unit of digital information, as well as a nod to the AI's technological nature. Distinctively, Byte acts as a gateway towards Ai adoption and stands out in the crypto space due to its zero-tax policy, a feature that is increasingly appealing to many investors. Additionally, it upholds the principles of transparency and investor trust by having its liquidity permanently burned and the contract ownership renounced. This ensures that Byte remains a community-driven project, with its fate firmly in the hands of its holders. The combination of a playful theme, generative AI, and a nod to a tech icon makes Byte an intriguing addition to the meme token ecosystem, especially AI related meme coins.  Through pioneering AI this story has grown more and more robust and continues to evolve, Byte pledges its dedication to community efforts and and has consistently appeared in the Top 10 of LunarCrush’s social engagement leaderboards on multiple occasions.

BYTE

$BYTE.X is trending as an AI meme coin linked to Elon Musk's Grok, sparking community excitement. The "Byte Army" is actively promoting the token, emphasizing its community-owned nature and potential in the AI and meme coin sectors. Discussions also highlight whale accumulation and positive sentiment from LunarCrush.

Memecoin on Cronos launched by the Cro Crow community

crow with knife

Enthusiastic community members are actively promoting $CAW.X, a memecoin known as "crow with knife", across various chains. The community emphasizes its deflationary nature and strong social presence, encouraging others to join and "caw caw" their way to potential gains. Mentions of "layer zero burn mechanism in place" and "crow with knife is the only option" highlight key community talking points.

BlackBerry Ltd. engages in the provision of intelligent security software and services. It operates through the following segments: Cybersecurity, Internet of Things (IoT), and Licensing and Other. The Cybersecurity segment includes the brand Cylance, BlackBerry Spark, AtHoc, and SecuSUITE. The IoT segment focuses on software licenses, support, maintenance, and professional services. The Licensing and Other segment involves the intellectual property licensing arrangements and settlement awards. The company was founded by Michael Lazaridis, James Laurence Balsillie, and Douglas E. Fregin on March 7, 1984 and is headquartered in Waterloo, Canada.

BlackBerry Ltd

BlackBerry is trending as investors discuss its partnerships with major tech companies like AMD and Nvidia, particularly regarding QNX's role in automotive and robotics. Community members are highlighting the company's potential for growth and a possible breakout, fueled by anticipation for upcoming earnings. The conversation also includes discussions around technical analysis, market manipulation, and BlackBerry's long-term prospects as a software and cybersecurity player.

Moonlake Immunotherapeutics operates as a clinical-stage biotechnology company. It offers tri-specific Nanobody, Sonelokimab to address significant unmet needs in inflammatory skin and joint diseases. The company was founded by Kristian Reich, Jorge Santos da Silva, and Arnout Ploos van Amstel in 2021 and is headquartered in Zug, Switzerland.

MoonLake Immunotherapeutics - Ordinary Shares - Class A

MoonLake Immunotherapeutics is trending due to positive Phase 2 trial results for their hidradenitis suppurativa treatment, sonelokimab, which has sparked considerable excitement and discussion within the biotech community. Community members are actively debating the potential for a buyout, comparing the company's prospects to competitors, and analyzing the implications of a possible public offering. The stock's movement is also influenced by discussions about short squeezes and technical indicators.

BrokeCoin is a meme-meets-utility cryptocurrency project operating under the ethos of Transparency, Community, and Respect. Formally registered as an LLC in Wyoming, USA, BrokeCoin is building an expansive ecosystem that combines light-hearted spirit of meme culture with real-world crypto utilities—spanning gaming, staking, NFTs, web services, and an e-commerce platform. Brokecoin believes in developing useful and interesting meme-inspired utilities to both service the crypto industry, and generate value for holders.

Brokecoin

Brokecoin is trending due to its recent listing on Bifinance, generating excitement about increased liquidity and exposure. The community emphasizes its consistent 'grind,' utility development, and active developer, setting it apart from other meme coins. Many express bullish sentiment and highlight the project's commitment to delivering on promises, with some mentioning an upcoming burn event.

ResMed, Inc. engages in providing digital health and cloud-connected medical devices. Its digital health technologies and cloud-connected medical devices transform care for people with sleep apnea, chronic obstructive pulmonary disease, or COPD, and other chronic diseases. The firm operates through the Sleep and Respiratory Care and Software as a Service segments. The Sleep and Respiratory Care segment engages in the sleep and respiratory disorders sector of the medical device industry. The Software as a Service segment provides business management software as a service to out-of-hospital health providers. The company was founded by Peter C. Farrell in June 1989 and is headquartered in San Diego, CA.

Resmed Inc.

ResMed ($RMD) is trending due to speculation around a potential partnership or acquisition with Incannex ($IXHL), fueled by positive Phase 2 results for Incannex's sleep apnea pill and a ResMed advisor on Incannex's clinical advisory board. Community members are discussing the strategic implications of a potential deal, with some suggesting it could revolutionize sleep apnea treatment. The community highlights the potential for a significant market impact should Incannex and ResMed collaborate.

Linea is the Layer 2 built from first principles to strengthen Ethereum and the entire ETH economy. Every aspect of its design—from its productive ETH burn mechanics, and capital efficient native yield, to its underlying Ethereum-equivalent zk tech—amplifies the value and utility of Ethereum Mainnet. All of this is backed by the largest ecosystem fund in the space, managed by the most trusted Ethereum builders. With institutional-grade infrastructure, and deep integration across DeFi, Linea is the best chain for ETH capital, where every transaction and every block strengthens Ethereum. Linea is where Ethereum wins.

Linea

Linea is trending as the community discusses its potential integration with SWIFT, a global banking network, with some suggesting it could be a competitor to Ripple ($XRP.X). There is excitement around the possibilities for the Ethereum ecosystem and Linea's role in it, with some users highlighting its newness and potential for growth.

Ouster, Inc. engages in the provision of high resolution digital lidar sensors that offer advanced 3D vision to machinery, vehicles, robots, and fixed infrastructure assets. The company was founded by Angus Pacala and Mark Frichtl on June 30, 2015 and is headquartered in San Francisco, CA.

Ouster Inc - Ordinary Shares - Class A

OUST is trending as investors react to news of increasing adoption of its lidar technology in diverse sectors like traffic management (Utah deployment) and security, and a potential breakout into the $100B security market. Bullish sentiment is fueled by consecutive quarters of revenue growth, zero debt, and growing cash reserves, with some community members anticipating a rise to $50. Discussions also highlight OUST as a key player in the physical AI space and a potential acquisition target.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Oric Pharmaceuticals, Inc. (ORIC) Now Trades Above Golden Cross: Time to Buy?

When a stock experiences a golden cross technical event, good things could be on the horizon. How should investors react?

Oric Pharmaceuticals, Inc. (ORIC) is a Great Momentum Stock: Should You Buy?

Does Oric Pharmaceuticals, Inc. (ORIC) have what it takes to be a top stock pick for momentum investors? Let's find out.

All You Need to Know About Oric Pharmaceuticals (ORIC) Rating Upgrade to Buy

Does Oric Pharmaceuticals (ORIC) Have the Potential to Rally 104.99% as Wall Street Analysts Expect?

What Makes Oric Pharmaceuticals, Inc. (ORIC) a Strong Momentum Stock: Buy Now?

Wall Street Analysts Predict a 131.33% Upside in Oric Pharmaceuticals (ORIC): Here's  What You Should Know

Oric Pharmaceuticals' stock hit its highest levels in three months on Thursday after the company unveiled promising preliminary results from its Phase 1b trial of ORIC-944, an AR inhibitor for metastatic castration-resistant prostate cancer (mCRPC).Shares of the pharma company soared 33.5% to close at $7.97 on Thursday.&nbsp;The company said that the trial showed potentially strong performance in both efficacy and safety, as 59% of patients reached a PSA50 response rate.&nbsp;This means that over half of the study participants saw an over 50% reduction in prostate-specific antigen (PSA) levels.Nearly all of these PSA responses were confirmed, and 24% of patients achieved PSA90 responses, indicating a 90% drop in PSA levels.The drug was tested with two established AR inhibitors — apalutamide (Erleada) and darolutamide (Nubeqa) — and PSA responses were consistent across all doses and both combinations.&nbsp;Most patients remained on therapy, with several approaching or surpassing one year of treatment duration.The safety profile was favorable because most adverse events were categorized as Grade 1 or 2.&nbsp;A single Grade 3 diarrhea event occurred, while no Grade 4 or 5 treatment-related events were linked to the medication.Meanwhile, ORIC also announced a $125 million private placement, which it said would extend its cash runway into the second half of 2027, covering the expected readout of its first global Phase 3 trial in 1H 2026.The initiation of ORIC's global registrational Phase 3 trial for ORIC-944 is planned for the first half of 2026.On Stocktwits, retail sentiment was ‘extremely bullish’ amid a 194% surge in 24-hour message volume.One user expressed optimism about the stock soon reaching $10 again.&nbsp;<stembedurl>https://stocktwits.com/OK78/message/616104324</stembedurl>However, another user questioned the private placement, suggesting it might be a setup for short sellers.They cited concerns over the company’s recent $125 million PIPE financing last year, which was initially expected to last through late 2026.&nbsp;“So, in the period of 12 months, they've diluted the stock with $250 million of new shares.”<stembedurl>https://stocktwits.com/Any_Day_Now/message/616156552</stembedurl>The stock has declined 3.5% so far in 2025.For updates and corrections, email newsroom[at]stocktwits[dot]com.

Portrait of a doctor woman on the background of stock charts. | Image source: Getty Images

Oric Pharma Stock Hits 3-Month High On Promising Results In Prostate Cancer Trial

The company also announced a $125 million private placement to fund its upcoming Phase 3 trial for ORIC-944 in metastatic prostate cancer.

Equity

ORIC Stock Surges on Upbeat Initial Data From Prostate Cancer Study

Cutting-Edge Cancer Therapies Lead the Way into a Transformative Year

Cutting-Edge Cancer Therapies Lead the Way into a Transformative Year Cutting-Edge Cancer Therapies Lead the Way into a Transformative Year PR Newswire VANCOUVER, BC, Jan. 15, 2025 Issued on behalf...

OpenBench and ORIC Pharmaceuticals Launch Success-Driven Discovery Collaboration

OpenBench and ORIC Pharmaceuticals Launch Success-Driven Discovery Collaboration OpenBench and ORIC Pharmaceuticals Launch Success-Driven Discovery Collaboration PR Newswire SAN FRANCISCO, Sept. 17...

Oric Pharmaceuticals, Inc. is a clinical stage biopharmaceutical company, which engages in the development of cancer treatments that address mechanisms of therapeutic resistance. It specializes in hormone-dependent cancers, key tumor dependencies, and precision oncology. The company was founded by Charles L. Sawyers, Richard A. Heyman, and Scott Lowe in 2014 and is headquartered in South San Francisco, CA.

ORIC Pharmaceuticals Inc

Will the U.S. government shut down in 2025? 
 
*Powered by Polymarket

Current Price	$11.12
Prev Close	$10.41
Open	$10.43
Dividend Yield	0.00%
50-Day Moving Average	$10.39
Beta	1.36
Avg. Volume	761,154.90
PE Ratio	-5.88

52-Week High	$14.67
52-Week Low	$3.90
Market Capitalization	$1.08B
EPS (Annual)	-$1.83
Price to Book	2.96
Revenue Per Employee	$0.00
Enterprise Value/EBITDA	N/A

ORIC
ORIC Pharmaceuticals Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest ORIC News

ORIC ORIC Pharmaceuticals Inc